Double immune checkpoint inhibitor therapy for unresectable pleural mesothelioma rarely induces hyperprogressive disease: a case report
HPD is a mode of progression for ICI-treated PM patients. Further investigation is needed to better define and anticipate HPD in these patients.
Authors
- J.B. Auliac (ORCID: https://orcid.org/0000-0002-6400-7506)
- Isabelle Monnet (ORCID: https://orcid.org/0000-0003-3279-9569)
- C. Chouaïd (ORCID: https://orcid.org/0000-0002-4290-5524)
- F. Viñas
- L. Jabot
- G. Rousseau-Bussac (ORCID: https://orcid.org/0000-0003-4706-0900)
- Gilles Mangiapan (ORCID: https://orcid.org/0009-0003-7374-6081)
- Jean‐Baptiste Assié (ORCID: https://orcid.org/0000-0002-9749-4937)
- G. Naulleau (ORCID: https://orcid.org/0009-0007-7621-2199)
- Amel Boudjemaa
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Sorbonne Université (FR)
- Centre de Recherche des Cordeliers (FR)
- Hôpital Intercommunal de Créteil (FR)
Publication Details
- Journal
- Translational Lung Cancer Research
- Published
- 2024-09-01
- DOI
- https://doi.org/10.21037/tlcr-24-382
- Citations
- 2
- Primary Topic
- Occupational and environmental lung diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.84